Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance-Reference-Cited by-同舟云学术

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

Published:2018-08-08 Issue:5 Volume:104 Page:890-899
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Zamek-Gliszczynski Maciej J.¹,Taub Mitchell E.²,Chothe Paresh P.³,Chu Xiaoyan⁴,Giacomini Kathleen M.⁵,Kim Richard B.⁶,Ray Adrian S.⁷,Stocker Sophie L.⁸,Unadkat Jashvant D.⁹,Wittwer Matthias B.¹⁰,Xia Cindy¹¹,Yee Sook-Wah⁵,Zhang Lei¹²,Zhang Yan¹³,

Affiliation:

1. Quantitative Drug Disposition, GlaxoSmithKline; King of Prussia Pennsylvania USA

2. Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim; Ridgefield Connecticut USA

3. Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals; Boston Massachusetts USA

4. Department of Pharmacokinetics; Pharmacodynamics and Drug Metabolism, Merck & Co.; Kenilworth New Jersey USA

5. Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine; University of California; San Francisco California USA

6. Division of Clinical Pharmacology, Department of Medicine; Western University; London ON Canada

7. Clinical Research, Gilead Sciences; Foster City California USA

8. Department of Clinical Pharmacology & Toxicology; St Vincent's Hospital, Sydney, NSW, Australia & St Vincent's Clinical School; UNSW Sydney NSW Australia

9. Department of Pharmaceutics; University of Washington; Seattle Washington USA

10. Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche; Basel Switzerland

11. Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International; Cambridge Massachusetts USA

12. Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration; Silver Spring Maryland USA

13. Drug Metabolism Pharmacokinetics & Clinical Pharmacology, Incyte; Wilmington Delaware USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.1112/fullpdf

Reference103 articles.

1. Membrane transporters in drug development;International Transporter, C.;Nat. Rev. Drug Discov.,2010

2. Emerging clinical importance of hepatic organic cation transporter 1 (OCT1) in drug pharmacokinetics, dynamics, pharmacogenetic variability, and drug interactions;Zamek-Gliszczynski;Clin. Pharmacol. Ther.,2017

3. The effect of famotidine, a MATE1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin;Hibma;Clin. Pharmacokinet.,2016

4. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics;Higgins;Drug Metab. Dispos.,2012

5. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects;Song;J. Acquir. Immune Defic. Syndr.,2016

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. OCTN1 (SLC22A4) displays two different transport pathways for organic cations or zwitterions;Biochimica et Biophysica Acta (BBA) - Biomembranes;2024-02

2. Membrane transporters in drug development and as determinants of precision medicine;Nature Reviews Drug Discovery;2024-01-24

3. Is Overexpression of the Plasma Membrane Transporter (SLC29A4) a New Option to Stratify Patients with High-Risk Neuroblastoma for Treatment with¹³¹I-mIBG?;Journal of Pharmacology and Experimental Therapeutics;2023-11-15

4. Structural and mechanistic basis of substrate transport by the multidrug transporter MRP4;Structure;2023-11

5. Carrier-Mediated Delivery of Low-Molecular-Weight N-Containing Drugs across the Blood–Brain Barrier or the Blood–Retinal Barrier Using the Proton-Coupled Organic Cation Antiporter;Future Pharmacology;2023-10-12